Latest Content

The FDA has approved oveporexton (Orzeyful), the first orexin agonist for narcolepsy type 1, based on phase 3 data showing broad symptom improvement.

Lab abnormalities can emerge between visits, and pharmacists may be able to catch uncontrolled hematocrit, adherence issues, or access barriers early.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

FDA advisers overrode their own scientists to back 6 peptides for compounding, even as safety data remains thin and gray-market risks persist.

Basement membrane composition actively drives NSCLC invasion, metastasis, and treatment resistance, a review finds, rather than serving as passive scaffolding.

Fix cardiorenalmetabolic care gaps: define ownership, task-shift screening, boost uACR testing, and tackle obesity-driven equity barriers.

Based on these results, the investigators are extending their follow-up into adolescence.

Clinicians at a Chicago Population Health Roundtable say atopic dermatitis biologic therapy is delayed by several key obstacles.

County-level CRC mortality was higher in areas with limited broadband access, higher smoking rates, and rurality.